Coronavirus

Pfizer and Moderna decline request by J&J to study the risks of blood clots – WSJ

cde.news desk 16 April 2021, 14:45 · 1 min read

epa09097508 Medical staff member prepares shots of the Janssen (Pharmaceutical Companies of Johnson & Johnson) vaccine against Covid-19 during a vaccination operation organized by St. John's Well Child and Family Center in Los Angeles, California, USA, 25 March 2021. St. John's Well Child and Family Center, the Los Angeles County Federation of Labor and immigrant rights groups organized a press conference prior to the vaccination operation to call for immigrants, including undocumented people, to be prioritized in the COVID-19 vaccine rollout. About 400 immigrant community members will be receiving their COVID-19 vaccines throughout the day at the site. EPA-EFE/ETIENNE LAURENT

(Reuters) – Johnson & Johnson had reached out to rival COVID-19 vaccine makers to join in an effort to study the risks of blood clots, but Pfizer Inc and Moderna declined, the Wall Street Journal reported on Friday.

Only AstraZeneca, which had been buffeted by similar blood-clotting concerns for weeks, agreed, the report said, citing people familiar with the matter. (https://on.wsj.com/2Q7E4Ho)

(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)

Filed under Coronavirus

Topics Coronavirus J&J Johnson and Johnson Moderna vaccine

Pfizer and Moderna decline request by J&J to study the risks of blood clots – WSJ

More from Coronavirus

Two million Britons suffer long COVID symptoms

CDC says JN.1 variant accounts for about 86% of COVID cases in US

WHO classifies JN.1 coronavirus strain as ‘variant of interest’